传奇生物 (LEGN.US) 2026年第三季度业绩电话会
文章语言：
简
繁
EN
Share
Minutes
原文
会议摘要
Carvykty net sales rose ~36% YoY to $710M, with second/third-line patients comprising 50% of US apheresis volume; global sites reached 373. Five-year data show 50% PFS without further therapy and 69% OS, with consistent safety. NCCN now favors BCMA CAR T over T-cell engagers. An investigational in vivo CD19/CD20 CAR T (LB2501) received FDA IND clearance, showing 100% ORR and CR at dose level 2 with favorable safety. Financials: revenue up 32% YoY, gross margin 58%, operating margin positive 6% excluding a one-time credit, adjusted net income $55.6M, cash ~$853M, no long-term debt. Pipeline includes CART-5 readout in 2027, CART-6 beyond, and LB2505 under collaboration. International growth is strong in Europe, supported by geography and single-payer systems. Management targets double-digit Carvykty growth in 2027 and sustained profitability.
会议速览
Legend Biotech's Q3 2026 Earnings Call Highlights CEO's Vision and Financial StrengthThe earnings call for Legend Biotech's Q3 2026 emphasizes the company's financial and commercial strength, highlighting the CEO's priorities to maximize kaity, advance the pipeline, and ensure sustained profitability, while underscoring the organization's innovative capabilities and patient-focused approach.
Significant Growth in Cell Therapy Sales and Pipeline AdvancementsCapEx Aq net trade sales surged 36% YoY, driven by US market adoption and new country launches. Long-term efficacy of cell therapy in multiple myeloma was highlighted, with FDA clearance for a novel in vivo therapy. The company's robust pipeline, including advanced CAR T and in vivo platforms, supports its strategy for sustainable growth and profitability.
Carvic's Global Growth & US Market Expansion in Earlier Treatment SettingsCarvic achieved significant global growth, driven by increased adoption in earlier treatment settings and expanded treatment networks. In the US, second and third-line patients accounted for 50% of apheresis volume, reflecting growing physician confidence in Carvic's benefits. NCCN guidelines now prefer Car T over T cell engagers, supporting Carvic's market position. Focus remains on operational execution, treatment center support, and patient access.
Strong Financial Performance and Scalable Business Model Drive Carve's Growth and ProfitabilityRevenue grew 32% year-over-year, with improved gross margins reaching 58% and operating margin turning positive at 6%. The company maintained a strong balance sheet with $853 million in cash and no long-term debt, supporting growth and innovation. Investments in commercial execution, manufacturing, and pipeline opportunities are yielding long-term profitability, with Q3 adjusted net income of $55.6 million.
Investment Priorities, Growth Strategies, and Pipeline Advances in Cell TherapyThe dialogue discusses continued investment in cell therapy, emphasizing the Envivo CAR T platform and global patient access expansion. It highlights the presentation of long-term data for Kavik and the advancement of the next-generation pipeline with SD clearance. The conversation also touches on competitive analysis, particularly regarding a competitor's BCMA CAR T, underlining the unique profile and extensive patient data of Carvic. The company reaffirms its goal to achieve profitability by 2026, driven by global growth and operational discipline.
Strategic Focus on Early Line Therapy for Franchise Growth and Dose Responsiveness in 2501 TrialThe dialogue discusses the strategic emphasis on early line therapy for product growth, noting the shift towards earlier treatment lines and the impact of NCCN guidelines. It also addresses the 2501 trial, anticipating dose responsiveness data at Ash, with a focus on optimizing efficacy at dose level II.
High Response Rates Observed in Clinical Trial Patients at Levels 2 and 3A clinical trial reveals a 100% response rate among 8 level 2 patients and over 60% among 5 level 3 patients, showcasing promising outcomes.
Estimating Carta 2.5 and 2.6 Readout Timelines and BCMA CAR T Competitive LandscapeThe dialogue discusses the anticipated timeline for top line results of Carta 2.5 and 2.6, emphasizing the necessity to wait for event accrual. It also addresses the competitive advantage of BCMA CAR T administered before bispecifics, advocating for its superior patient outcomes as supported by NCCN guidelines.
Long-Term Growth Outlook for Carvic Despite Competitive Challenges and Launch DelaysSpeakers discuss expecting substantial year-over-year growth for Carvic globally, despite competitive headwinds and launch delays in certain markets. They highlight the potential for long-term growth, emphasizing the opportunity to educate physicians and patients on the benefits of Car T therapy, with the goal of reaching a $5 billion plus business potential by 2027.
Q&A on Incremental Patient Growth and DL Three Cohort Data Follow-UpDiscussion centered on expectations for incremental patient growth starting Q4, with emphasis on ongoing expansion in second and third lines. Clarification sought on additional follow-up data for DL three cohort at Ash, with confirmation of continued growth into early next year.
Update on Data in Ash Discussed During Q&A SessionAdditional updated data in Ash was mentioned, and a question from Edward Tenho was addressed, indicating ongoing discussion and updates regarding specific data points.
Exploring IO Candidate 25 Oh 1 for Autoimmune Diseases Beyond B-Cell LymphomaDiscussion revolves around the development of IO candidate 25 oh 1 for autoimmune diseases, considering its potential beyond b-cell lymphoma, and exploring other IL candidates using the enabler platform and Oppo 10.41.
South African Company's Strategic Move: Advancing IIT in China through Early Proof ConceptA leading South African company outlines its plan to advance its presence in China by initiating an IIT study to achieve an early proof concept, showcasing its commitment and capabilities in international technology integration.
Analysis of Market Demand, Growth Momentum, and Competitive Landscape in Cancer TherapiesDiscussion focuses on market trends, patient distribution, and competitive pressures affecting cancer therapies, emphasizing early line treatment advantages and future franchise potential.
Discussion on Initiating Phase 1 Myeloma Study in China and Advancing to US INDThe dialogue revolves around the timeline for starting a Phase 1 myeloma study in China and the requirements for advancing to an Investigational New Drug (IND) application in the US. It is noted that the study's initiation is imminent, contingent on the collaboration between Ni Biotech and Johnson & Johnson. Specifics are withheld pending official confirmation and future disclosures.
International Expansion of Car T Therapy: Growth Drivers and Reimbursement DynamicsDiscussed the global expansion of Car T therapy, highlighting growth in established and new markets, favorable European dynamics, and the impact of single-payer systems on reimbursement, projecting continued international growth as a key driver for the product's potential reaching over 5 billion.
Analysis of Referral Patterns for Covi and Development of 2501 in CAR T-Cell TherapyThe dialogue discusses the growth in patient referrals for Covi treatment, noting both new physician referrals and increased referrals from existing sources, emphasizing educational efforts to plan treatment journeys. It also covers the development of 2501, focusing on CAR T-cell characteristics and expansion, with an observation that expanded cells were predominantly CD8 positive effector memory cells with limited differentiation and exhaustion, highlighting ongoing translational analysis to monitor T cell phenotypes.
Discussion on Representativeness of CART 5 Trial Control Arm and Efficacy Benchmarks in Real-World PatientsThe dialogue discusses the representativeness of the CART 5 trial's control arm in reflecting real-world patients and current treatment patterns, emphasizing its adequacy and appropriateness as confirmed by FDA consultation. It also addresses the shift towards quad therapy and the importance of CART 5 data for transplant-ineligible or deferred patients, highlighting the trial's significance in demonstrating benefits over the control arm.
Investigating Response Thresholds and Dose Expansion in Early Phase StudyDiscussion focused on the initial findings from a study, noting a response threshold with no reactions at lower doses (DL 1 and 2) but 100% at higher doses. The need for longer follow-up and more patients to understand the correlation between dose expansion and responses was highlighted.
要点回答
Q：What are the key priorities of Ingrid Zong as the new CEO of Legend Biotech?
A：Ingrid Zong's key priorities as the new CEO of Legend Biotech are to: 1) Maximize Kavi, 2) Advance the next generation pipeline, and 3) Strengthen execution on all fronts to deliver sustained profitability.
Q：How did the third quarter's net trade sales grow year over year, and what were the main drivers?
A：In the third quarter, net trade sales increased approximately 36% year over year to 710 million. Growth was driven by continued adoption in the early line settings in the US and new country launches, with net trade sales increasing 19% in the US and 86% outside of the US on a year-over-year basis.
Q：What are the notable results from the long-term follow-up data of the targeted two cohort A study at the 2026 International Myeloma Society annual meeting?
A：The long-term follow-up data from the targeted two cohort A study at the 2026 International Myeloma Society annual meeting further strengthened the evidence supporting the potential impact of Kavi in early line multiple myeloma. Specifically, the five-year follow-up analysis of the Cardioid 2 cohort A in patients with B cells or refractory multiple myeloma showed strong durability responses and consistent clinical profile without new car T cell-related neurotoxicity.
Q：What FDA clearance was obtained for Lb 2501 and what does this represent?
A：Lb 2501 received FDA clearance for an Ind application, representing an important achievement step as the company advances its next-generation cell therapy program for relapsed or refractory B cells non-Hodgkin lymphoma.
Q：What are the future plans for Lb 2501 in clinical development?
A：The future plans for Lb 2501 in clinical development include a phase 1A study to confirm and further characterize its efficacy in the US clinical setting, followed by phase 1B to broaden evaluation across multiple B cell malignancies and inform patient selection. Subsequently, Lb 2501 is intended to advance into phase 2 in an appropriately selected patient population to further characterize and confirm efficacy and safety. These plans are based on insights from ongoing investigator-sponsored studies in China.
Q：What are the key factors contributing to the company's increased breadth of opportunities?
A：The key factors contributing to the company's increased breadth of opportunities include the cost of the pipeline, the company's execution focus, the continued success of the IBV legend in multiple myeloma, and the expansion of the global demand for Car T therapies.
Q：What updates were provided regarding the company's pipeline and execution efforts?
A：The company continues to advance its differentiated cell therapy programs, including its next generation in vivo platform. They aim to achieve company-wide profitability for the full year 2026 on an adjusted net income basis and remain focused on operational execution, treatment center support, education, patient access, and ensuring that both physicians and patients can benefit from their therapies.
Q：What were the company's financial performance and growth indicators for the quarter?
A：The company's financial performance showed a 32% year-over-year increase in total revenue to approximately $710 million, driven by continued global demand for Car T and commercial expansion. Adjusted earnings showed a positive 6% operating margin, with revenue growth, improving operating efficiency, and a strong balance sheet. Gross margins improved to 58%, and research and development and selling, general, and administrative expenses decreased year over year. The company remains confident in achieving full-year profitability on an adjusted net income basis.
Q：What impact did the recent NCCN guideline updates have on the company's business?
A：The recent NCCN guideline updates have highlighted that BCMA Car T is preferred over T cell engagers when both are viable options, due to established efficacy of T cell engagers following Car T cell therapy failure. These updates provide clear evidence that the company's strategy is executing across objectives, and they are focusing on operational execution and market penetration as physician familiarity grows.
Q：How did the company's in vivo platform and cell therapy contribute to the revenue growth?
A：The company's focus on operational execution, treatment center support, and education, along with patient access, has contributed to the revenue growth. The revenue growth is primarily driven by the ongoing expansion of Car T across geographies and treatment settings, supported by the in vivo platform and cell therapy.
Q：What are the company's expectations for the remainder of the year?
A：The company's expectations for the remainder of the year are centered on three key priorities: continuing to drive global growth as patient access expands and adoption deepens, advancing the pipeline and translating innovation into future value-creating opportunities, and delivering on the goal of achieving company-wide profitability in 2026 on an adjusted net income basis.
Q：What are the updated data findings on the competitor BCMA car T discussed in the Ash presentation?
A：The updated data on the competitor BCMA car T showed a 100% response rate and a 60% compute response rate for level 3 patients, with a median follow-up of 4.8 months. There were no DLTs, no ICS, and no non-ICS neurotoxicities reported. The strong signal for DL2S was maintained and strengthened.
Q：How does the BCMA car-T therapy from the company compare in efficacy and safety to competitors, especially in the context of bridging therapy?
A：The BCMA car-T therapy from the company has a unique profile, with five-year data and treatment of 15,000 patients. It demonstrates both long-term survival and efficacy in the later line setting. The company notes they have improved efficacy in the fourth setting compared to previous data. They have also made strides in educating the community about the importance of bridging therapy to reduce tumor burden and the risk of long-term or delayed neurotoxicity. The company believes real-world data, where they treat more patients in a week than the competitor has shown in their entire program, will provide further insight into the therapy's effectiveness.
Q：When is the anticipated transition from driving key use into earlier lines of therapy to sales growth in the U.S. expected?
A：The company has been strategically focused on the early line setting, which has led to an increase in its business coming from second and third lines despite competition from bispecifics in earlier lines. They expect that the migration of business towards earlier lines, along with the NCCN guidelines promoting Car T first and the belief that earlier is better for BCMA car-T in terms of efficacy, safety, manufacturing, and patient selection, will continue to drive share gains in the early lines and ultimately result in product growth.
Q：What is the expected timeline for top line results for Carta 25 and Carta 26 trials?
A：For Carta 25, the company previously stated that a readout would be expected in 2027, pending the accrual of necessary events. For Carta 26, results would be beyond that, pending similar event accrual. The company emphasizes that these timelines are dependent on event accrual and that long PFS has been demonstrated in the literature for similar trials, with the potential for leveraging MRD data to support an early read that correlates with long-term survival.
Q：How is the company planning to educate physicians and treatment centers about the benefits of Car T before bi specifics?
A：The company is working with its partner to educate both the community referral physicians and the authorized treatment centers about the benefits of offering Car T therapies in sequence rather than focusing on the specific product choice.
Q：What are the company's expectations for sales growth in Q4 and the full year 2027?
A：The company still expects substantial year-over-year growth on a global basis. For Q4, sales consensus is at the higher end of the range, primarily driven by changes in launch dynamics outside of the US and slower earlier line share growth in the US. For the full year 2027, double-digit growth year over year is expected for Car T, but the net trade sales consensus could be at the higher end of the anticipated scenarios due to launch delays in some markets and slower earlier line share growth in the US.
Q：How is the competitive landscape being addressed in educating physicians and patients about Car T therapies?
A：The company is engaging in extensive education to ensure that a broad spectrum of physicians and patients understand the data supporting Car T therapies, especially in second and third line treatments, which is a longer-term selling cycle. They are utilizing tools and data from NCCN and the positive results with Car 4 to effectively communicate the value proposition.
Q：What proportion of patients in the second and third lines have been BCMA exposed, and what does this imply for the company's future growth?
A：Between 15 and 20% of patients in the second and third lines have been BCMA exposed, leaving an opportunity for the company with the remaining 80-85% who have not been exposed. This indicates potential for continued business growth and achieving the potential of a $5 billion plus business.
Q：What are the company's expectations for the transition of patients from second to third line in the fourth quarter and future impact on the business?
A：The company expects to continue growing in the second line and third line throughout the rest of the year and into early next year. They also anticipate that the IO candidate 25-01 will provide incremental patients beyond the fourth quarter.
Q：What are the company's plans for the DL3 cohort data set for 25-01, and when will updated data be available?
A：The company plans to update the DL3 cohort data set for 25-01 at the ASH conference.
Q：What is the company's strategy for developing 25-01 in autoimmune diseases?
A：The company is exploring all options and is very interested in autoimmune diseases using their enabler platform. One of the candidates being explored is 25-010.41. Their strategy includes conducting Investigator Initiated Trials (IIT) to achieve early proof of concept.
Q：What competitive changes are anticipated in the marketplace?
A：The marketplace will continue to become increasingly competitive with additional bispecifics coming onto the market and competition not only from approved bispecifics but also from new entrants.
Q：What is the current status regarding the start of the phase 1 study in myeloma in China?
A：The start of the phase 1 study in myeloma in China is very soon, but specifics are subject to the collaboration agreement between Ni Biotech and Johnson Johnson, and further details cannot be disclosed at this point.
Q：What factors contribute to the international growth of the company?
A：The company's international growth is driven by the launch of new markets, continued growth in established markets such as Germany, Spain, and Italy, and the emergence of smaller European markets like Belgium, Denmark, and Switzerland as contributors.
Q：What dynamics in Europe support the uptake of car T cell therapies?
A：In Europe, the favorable dynamics supporting car T cell therapies include the ease of access to larger academic centers and authorized treatment centers, well-established referral patterns, and the concept of a single-payer system that looks at the long-term value and cost-effectiveness of a one-time infusion, which is seen as a positive story for reimbursement and uptake.
Q：What are the observed characteristics of expanded CD 8 positive T cells in the IET study?
A：In the IET study, the expanded CD 8 positive T cells were predominantly CD 8 positive effectors with limited Th differentiation and a exhaustion associated transcriptional signature.
Q：How should the control arm of the Car 5 trial be interpreted in terms of real-world patients and efficacy benchmarks?
A：The control arm of the Car 5 trial, which is VRD, is seen as an adequate and appropriate control arm. With an increasing number of patients receiving quad therapy upfront, the plan is to support the filing with data showing a benefit from dextrose VRD. The study is believed to be meaningful, especially as more patients become transplant ineligible or deferred.
Legend Biotech Corp.
Follow
